TANG KEVIN purchased $33K of BOLD (indirect holdings)

TANG KEVIN purchased 13,812 indirectly-held shares of Boundless Bio, Inc. (BOLD) at $2.40 across 2 trades over 2026-11-13 to 2026-11-17. Filed jointly with TANG CAPITAL MANAGEMENT LLC (10% owner).

Original reporting
SEC EDGAR · TANG KEVIN, TANG CAPITAL MANAGEMENT LLC
Published Nov 17, 2026, 10:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 10:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BOLD
Bullish
medium confidence
Mentioned
$BOLD
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLDBullishLow
01

Why it matters

This provides a fresh, primary-source datapoint on insider behavior, which can influence short-term sentiment but does not change fundamentals on its own.

02

Market read

Traders may briefly re-rate sentiment on insider accumulation, but without accompanying operational news the impact is likely small.

03

What to watch

The purchase is indirect and the article does not clarify whether additional insider buying or selling occurred around the same period, limiting inference from one filing.

Relevance 4/10Novelty 5/10Timing: filed 2026-11-17, covering purchases from 2026-11-13 to 2026-11-17

Background

The article is an SEC Form 4 insider transaction disclosure for Boundless Bio, Inc. (BOLD).

Company-level read

Ticker impact

$BOLDBullishMedium confidence
Context

Boundless Bio disclosed a Form 4 showing Tang Kevin, a 10% owner, bought 13,812 shares in open-market trades at $2.40.

Expected impact

Likely limited upside bias as traders may interpret the purchase as confidence, but the effect should be muted versus operating or financing news.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure and the buyer is a 10% owner, but the article provides no new company-specific operational or guidance information.

Market effects

Minimal, as this is a single-company insider transaction with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

A 10b5-1 plan is explicitly marked as not pre-arranged, but the trades could still reflect liquidity management or diversification rather than a strong forward-looking view.

Key entities

  • Boundless Bio, Inc.

    Company whose shares were purchased in the disclosed insider transaction.

  • TANG KEVIN

    Reporter and 10% owner whose indirect open-market purchase was disclosed.

  • TANG CAPITAL MANAGEMENT LLC

    Joint filer listed as a 10% owner.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BOLDMed

Boundless Bio 3Q 2026: EPS ($0.23) — 10-Q Summary

Boundless Bio reported a 61.4% narrower net loss of $5.36M in Q3 2026, with EPS at ($0.23). The reduction was driven by lower clinical-trial spending, reduced facilities, and personnel costs. The company also announced a 75% workforce reduction and expects a merger with Serapha Bio to close in Q4 2026, with a pre-closing dividend of $44M-$48M.